A B S T R A C T It has been suggested previously that chlorpropamide and other hypoglycemic sulfonylureas interfere with hepatic triglyceride breakdown. Since ketogenesis from endogenous hepatic lipid stores is a measure of hepatic triglyceride hydrolysis, ketogenesis derived from endogenous lipids as well as ketogenesis derived from exogenously added isotopic oleate was determined in isolated hepatocytes from fasted rats in an attempt to identify the nature of the direct effects of sulfonylureas on hepatic lipid metabolism. Ketogenesis from endogenous lipids was inhibited by 1 mM chlorpropamide, while ketone production from exogenous oleate did not change. The effect of chlorpropamide on hepatic triglyceride metabolism was further studied in the isolated perfused liver of normal rats in the presence of a continuous [3H]oleate infusion and in isolated liver cells incubated in the presence of [3H]oleate. In liver perfusion experiments, 1 mM chlorpropamide enhanced the incorporation of tritium into triglycerides (but not other lipid classes) and increased both liver triglyceride content and triglyceride secretion. Using isolated cells similar effects could be demonstrated at 0.5 mM chlorpropamide.
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Chlorpropamide, tolbutamide, and carbutamide, all of which inhibited endogenous ketogenesis in isolated liver cells, also inhibited lysosomal triglyceride lipase activity in rat liver homogenates. The drugs were not inhibitory towards alkaline lipase activity.
Demethylglycodiazin (2-benzolsulfonamido-5-(,8-hydroxyethoxy)-pyrimidin), which did not inhibit endogenous ketogenesis in isolated liver cells, did not affect lysosomal lipase activity. The lysosomotropic INTRODUCTION For the last two decades hypoglycemic sulfonylureas have been widely used in the oral treatment of maturity onset diabetes. In addition to stimulating insulin secretion, a variety of extrapancreatic effects have been ascribed to these drugs, amongst which is a direct antiketogenic action on the liver (1) (2) (3) (4) . Although the antiketogenic effect of the sulfonylureas seems to be well established, the site of their inhibitory action is less clear. Hasselblatt (2) has shown that glycodiazin' and tolbutamide inhibit ketogenesis from endogenous hepatic lipids but not from an exogenously added tracer amount of [1-14C] palmitate in liver slices. Similarly, experiments carried out in our laboratory (3, 4) have demonstrated that the antiketogenic effect of chlorpropamide and carbutamide in the isolated rat liver perfused with a fatty acid-free medium largely disappears upon addition of octanoic or oleic acid to the perfusion medium.
The main difference between ketogenesis from endogenous lipids vs. ketogenesis from exogenous fatty acids is that in the former case, hepatic triglycerides must be hydrolyzed by a triglyceride lipase before the liberated fattv acids canl enter the activation and oxidation pathwavs which are common to ketogenesis from either endogenous or exogenous fatty acids. Since activation and oxidation of exogenous fatty acids were apparently not affected by the drugs in the above mentioned experiments, their inhibitory effect on endogenous ketogenesis has been postulated to involve an inhibition of hepatic triglyceride lipase activity (glycerol ester hydrolase E.C. 3.1.1.3).
In the present experiments we have examined in detail the direct effects of sulfonylureas on hepatic lipid metabolism. The results to be presented confirm the antiketogenic effects of these drugs from endogenous but not exogenous substrate and demonstrate that they cause an increase in hepatic triglyceride storage and release. In addition it is shown that the antiketogenic sulfonylureas inhibit lysosomal lipase activity.
METHODS
Animals. Livers were taken from male Wistar rats weighing 100-120 g and maintained on stock laboratory diet. For studies on ketogenesis, rats were starved for 24 h. Fed rats were used in the other experiments.
Liver perfusions. The operative technique was that of Hems et al. (5) modified as follows: the animals received no heparin before cannulation of the portal vein. Instead, after insertion of the portal cannula, the inferior caval vein was cut at a point below the kidney and the liver was immediately flushed with 20 ml of perfusion medium. The usual operative procedure was then continued. The closed circuit perfusion apparatus has been described in detail previously (3). Livers were perfused at 36°C for 135 min w%ith a cell-free mediumii (6) containing 200 mg/dl of glucose. Tritiated oleate (67,Ci/,umol) was converted to its sodium salt as described previouslv (6) . 100 or 150 ,umol of the labeled fatty acid, bound to albumin (6) Anialysis of the perfiusion mediumiz and the liver. Samiiples of perfusate were removed at various times during the experimenit. Lipids Nwere extracted from 1 ml of medium wvith 20 ml of chloroform:methanol (2:1, vol/vol) (7) . The extracts were washed with 0.2 vol of 0.1 N sodium hydroxide to remove excess FFA and evaporated to dryness under nitrogen. The residue was dissolved in 0.5 ml of chloroform and placed on 2-g silicic acid columns to remove phospholipids (8) . The columns were eluted with 10 ml of chloroform and the eluates analyzed for triglycerides by the method of Van Handel and Zilversmit (9) .
At the end of the experiment, livers were rapidly fluslhed with 25 ml of ice cold perfusion medium, and frozen between metal clamps previously cooled in liquid nitrogen. The frozen tissue was then pulverized in a mortar precooled with liquid nitrogen. Lipids were extracted from approximately 1 g of liver powder with 20 vol of chloroform:methanol (2:1, vol/vol) (7) . The extracts were washed with 0.2 vol of 0.02% Mg Cl2 (wt/vol) and evaporated to dryness under nitrogeni. The residue was taken up in 2.5 ml of chloroform per gram tissue and 0.5 ml of this volume was passed through silicic acid columns for the chemical determination of triglycerides as described above. 50-or 100-,J aliquots were spotted on thin-layer silicic acid chromatography plates (Merck A.G., Darmstadt, W. Germany) and the lipids separated according to Skipski et al. (10) .
Lipid bands were located with a 2', 7'-dichlorofluorescein spray and scraped off into liquid scintillation counting vials. The silicic acid powder was shaken for 60 min with 10 ml of Instagel (Packard Instrument, Co., Inc., Downers Grove, Ill.) and counted in a liquid scintillation spectrometer. 16 .7 mg of defatted (12) bovine serum albumin, and 0.5 mg of Triton X-100 (Rohm and Haas Co., Philadelphia, Pa.) per ml of buffer. These constituents were emulsified by homogenizing the mixture for 2 min in ice with an Ultra-Turrax homogenizer (Janke and Kunkel, Staufen, W. Germany). Within 30 min of preparation, 0.9 ml of this emulsion was mixed with 0.1 ml of homogenate and incubated in a shaking water bath at 37°C for 20 min when acid lipase activity was measured and for 60 min when alkaline lipase activity was measured. The liberated fatty acids were subsequently extracted from the incubation mixture (18) Effect of chlorpropaniide on triglyceride secretion by the perftused liver. The liver is the site of produiction of the sertumn triglycerides presenit in very low density lipoproteinis (19) (20) (21) . Siniee an enhanced accumtulation of hepatic triglvcerides miiight change hepatic triglvceride secretion rates, the triglyceride 4 Indicates significance at the P < 0.05 level. content of the perfuision miieditumn was followed after 64 and 124 min of perftusion in the presence of oleate. (Fig. 1 ): a sharp peak at pH 4.4, which represents the lysosomal enzyme (22) (23) (24) (25) (26) (27) , and a broad peak around pH 8-9, subdivided into a maximum at pH 8.2 , and one at pH 9.2. These maxima most probably reflect the activities of the microsomal enzyme with a pH optimum at 8 (24) and of the plasma membrane enzyme which has its optimum at pH 9-9.5 (23, 24) . Effect ofsulfonylureas on hepatic triglyceride lipase activity. Fig. 2 shows triglyceride lipase activity as a function of substrate concentration at pH 8.2 ( Fig.  2A) and at pH 9.2 (Fig. 2B) . Using the LineweaverBurk method, an apparent Km of 0.28 mM and a VmaX of 0.231 ,umol FFA/mg protein per 60 min were calculated for the lipase activity at pH 8.2. At pH 9.2, these values were 0.77 mM and 0.308 ,umol FFA/mg protein per 60 min. Fig. 3 shows the lysosomal lipase activity, assayed at pH 4.4, vs. substrate concentration. The acid lipase did not show straight forward hyperbolic kinetics over the range of substrate concentrations used.
Chlorpropamide,3 tolbutamide, and carbutamide, all of which were antiketogenic in isolated hepatocytes (Table VI) , significantly inhibited lysosomal lipase activity. In contrast, demethylglycodiazin, 3While all drugs were routinely tested at 5 mM, chlorpropamide was used at 4 mM concentration in the acid lipase assays because of its poor solubility at acid pH. the demethylation product of glycodiazin, which retains its blood sugar lowering capacity in vivo (2), but which is no longer antiketogenic in liver slices (2) or isolated hepatocytes (Table VI) was much less inhibitory. The same drugs had little or no effect on the alkaline lipases (Fig. 2) .
The fact that all the antiketogenic sulfonylureas tested inhibited acid lipase activity points towards a role of the lysosomes in hepatic triglyceride breakdown. Further evidence for this concept comes from the observation that the lysosomotropic drug chloroquine Tables IV and V , chlorpropamide also stimulates hepatic triglyceride secretion. The enhanced secretion rates are most likely due to the above proposed interference of the drug with hepatic triglyceride breakdown, which results in an increased accumulation of liver triglycerides. Other metabolic situations are known where a relative increase in hepatic triglyceride content results in an increased secretion. The fed liver, which esterifies considerable amounts of FFA, secretes more triglycerides than the fasted liver, which preferentially oxidizes the incoming fatty acids (33) . Moreover, sucrose feeding, which enhances esterification, also causes enhanced rates of triglyceride secretion (34, 35) .
The observations reported here indicate that concentrations of 0.5 and 1 mM chlorpropamide, which lie within the range of therapeutic blood levels (36) , are capable of altering hepatic triglyceride metabolism in acute experiments. It is not clear, however, whether the increased hepatic triglyceride levels might ultimately predispose to the development of fatty liver or whether the enhanced triglyceride secretion rates might cause hypertriglyceridemia. As with all in vitro and animal experiments these data cannot be directly extrapolated to human therapy. To our knowledge, no clinical reports have appeared clearly demonstrating that chronic sulfonylurea treatment might cause the above mentioned adverse effects. Such studies might be complicated by the fact that fatty liver as well as hyperlipidemia are not uncommon in diabetes. Nevertheless, it should be noted that Greenberg et al. (37) found higher lipoprotein levels in patients who had been switched from insulin to tol- Isolated hepatocytes from fasted rats were incubated without substrate. Results are expressed as means±SEM of the number of experiments given in parentheses (paired data). * Indicates significance at the P < 0.05 level.
butamide therapy, although blood sugar control was unchanged, and that Knick et al. (38) found higher serum triglyceride levels in sulfonylurea-treated patients than in insulin-treated diabetics, when serum triglycerides were plotted against the daytime mean sugar profile.4 It would, therefore, seem appropriate to examine more closely plasma triglycerides in patients chronically treated with sulfonylureas. Moreover, since sulfonylureas seem to interfere with hepatic intralysosomal lipid breakdown, it is not precluded that these drugs might also influence plasma lipid levels by inhibiting the peripheral intralysosomal breakdown of low density lipoproteins (39) .
